Apellis Pharmaceuticals Statistics
Share Statistics
Apellis Pharmaceuticals has 125.68M
shares outstanding. The number of shares has increased by 3.42%
in one year.
| Shares Outstanding | 125.68M |
| Shares Change (YoY) | 3.42% |
| Shares Change (QoQ) | 0.9% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,295 |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 28.77M, so 22.89% of the outstanding
shares have been sold short.
| Short Interest | 28.77M |
| Short % of Shares Out | 22.89% |
| Short % of Float | 30.2% |
| Short Ratio (days to cover) | 12.71 |
Valuation Ratios
The PE ratio is -19.98 and the forward
PE ratio is 101.71.
Apellis Pharmaceuticals's PEG ratio is
0.31.
| PE Ratio | -19.98 |
| Forward PE | 101.71 |
| PS Ratio | 5.06 |
| Forward PS | 1.3 |
| PB Ratio | 17.3 |
| P/FCF Ratio | -44.79 |
| PEG Ratio | 0.31 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Apellis Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.25,
with a Debt / Equity ratio of 2.06.
| Current Ratio | 4.25 |
| Quick Ratio | 3.81 |
| Debt / Equity | 2.06 |
| Debt / EBITDA | -3.04 |
| Debt / FCF | -5.32 |
| Interest Coverage | -4.08 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,108,321.99 |
| Profits Per Employee | $-280,678.01 |
| Employee Count | 705 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | 1.16M |
| Effective Tax Rate | -0.59% |
Stock Price Statistics
The stock price has increased by -58.82% in the
last 52 weeks. The beta is 0.72, so Apellis Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.72 |
| 52-Week Price Change | -58.82% |
| 50-Day Moving Average | 21.51 |
| 200-Day Moving Average | 29.42 |
| Relative Strength Index (RSI) | 34.14 |
| Average Volume (20 Days) | 2,290,008 |
Income Statement
In the last 12 months, Apellis Pharmaceuticals had revenue of 781.37M
and earned -197.88M
in profits. Earnings per share was -1.6.
| Revenue | 781.37M |
| Gross Profit | 663.64M |
| Operating Income | -164.98M |
| Net Income | -197.88M |
| EBITDA | -154.53M |
| EBIT | -156.32M |
| Earnings Per Share (EPS) | -1.6 |
Full Income StatementBalance Sheet
The company has 411.29M in cash and 469.78M in
debt, giving a net cash position of -58.49M.
| Cash & Cash Equivalents | 411.29M |
| Total Debt | 469.78M |
| Net Cash | -58.49M |
| Retained Earnings | -3.04B |
| Total Assets | 885.05M |
| Working Capital | 603.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -87.87M
and capital expenditures -403K, giving a free cash flow of -88.27M.
| Operating Cash Flow | -87.87M |
| Capital Expenditures | -403K |
| Free Cash Flow | -88.27M |
| FCF Per Share | -0.71 |
Full Cash Flow StatementMargins
Gross margin is 84.93%, with operating and profit margins of -21.11% and -25.32%.
| Gross Margin | 84.93% |
| Operating Margin | -21.11% |
| Pretax Margin | -25.18% |
| Profit Margin | -25.32% |
| EBITDA Margin | -19.78% |
| EBIT Margin | -21.11% |
| FCF Margin | -11.3% |
